

# Nicolas Mounier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2733508/publications.pdf>

Version: 2024-02-01

160  
papers

12,847  
citations

24978

57  
h-index

24179

110  
g-index

173  
all docs

173  
docs citations

173  
times ranked

10044  
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	0.6	1,552
2	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 4184-4190.	0.8	1,331
3	Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , 2003, 101, 4279-4284.	0.6	483
4	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1858-1867.	6.3	311
5	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. <i>Blood</i> , 2008, 112, 4824-4831.	0.6	304
6	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008, 111, 4463-4470.	0.6	292
7	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.	0.8	287
8	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNHO3-6B study): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 525-533.	5.1	257
9	The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4079-4087.	0.8	248
10	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 <sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4462-4469.	0.8	248
11	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 787-792.	0.8	239
12	Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 2006, 108, 2540-2544.	0.6	230
13	High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 440-446.	0.8	226
14	Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 4402-4406.	0.8	216
15	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	1.3	216
16	A Clinical Decision Support System for Prevention of Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2816.	3.8	205
17	Impact of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012, 30, 4317-4322.	0.8	168
18	Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 467-475.	0.8	165

#	ARTICLE	IF	CITATIONS
19	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013, 122, 3251-3262.	0.6	156
20	MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012, 119, 4619-4624.	0.6	145
21	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 202-215.	5.1	145
22	Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. <i>Blood</i> , 2003, 103, 1222-1228.	0.6	140
23	Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3614-3620.	0.8	137
24	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. <i>Blood</i> , 2006, 107, 3832-3840.	0.6	133
25	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013, 98, 1726-1731.	1.7	131
26	Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. <i>Blood</i> , 2006, 108, 4163-4169.	0.6	120
27	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase II study. <i>British Journal of Haematology</i> , 2002, 119, 726-739.	1.2	119
28	Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	0.8	113
29	Eight Cycles of ABVD Versus Four Cycles of BEACOPP <sub>escalated</sub> Plus Four Cycles of BEACOPP <sub>baseline</sub> in Stage III to IV, International Prognostic Score $\geq 3$ , High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2028-2036.	0.8	111
30	AIDS-Related Malignancies: State of the Art and Therapeutic Challenges. <i>Journal of Clinical Oncology</i> , 2008, 26, 4834-4842.	0.8	110
31	CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. <i>Blood</i> , 2002, 99, 2940-2947.	0.6	108
32	Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 1732-1740.	0.8	108
33	Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2005, 52, 1555-1563.	6.7	105
34	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 788-793.	2.0	102
35	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017, 52, 216-221.	1.3	102
36	Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. <i>Laboratory Investigation</i> , 2004, 84, 1512-1519.	1.7	100

#	ARTICLE	IF	CITATIONS
37	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1160-1170.	5.1	96
38	ABVD (8 cycles) versus BEACOPP (4 escalated cycles &#224 baseline): final results in stage III&#224IV low-risk Hodgkin lymphoma (IPS 0&#2242) of the LYSA H34 randomized trial. <i>Annals of Oncology</i> , 2014, 25, 1622-1628.	0.6	91
39	Autologous stem cell transplantation in elderly patients (&gt;=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <i>Haematologica</i> , 2008, 93, 1837-1842.	1.7	90
40	Prognostic value of baseline total metabolic tumor volume (TMTVO) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). <i>Annals of Oncology</i> , 2016, 27, 719-724.	0.6	90
41	Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Soci&#224 Fran&#224saise de Greffe de Moelle et de Th&#224rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> . 2010. 16. 78-85.	2.0	89
42	FDG-PET&#224driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017, 130, 1315-1326.	0.6	87
43	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	1.7	84
44	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B&#224cell non&#224Hodgkin lymphomas, ANRS HC&#22413 lympho&#224C study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	2.0	84
45	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 1854-1860.	0.6	83
46	Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015, 26, 958-966.	0.6	81
47	Young Patients With Non&#224Germinal Center B-Cell&#224Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> . 2014. 32. 3996-4003.	0.8	79
48	The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. <i>Cancer</i> , 2007, 110, 1361-1369.	2.0	77
49	BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. <i>Oncotarget</i> , 2012, 3, 490-501.	0.8	75
50	Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 773-780.	0.6	69
51	Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas. <i>European Radiology</i> , 2007, 17, 843-849.	2.3	65
52	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2009, 20, 1985-1992.	0.6	64
53	Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2007, 109, 2183-2189.	0.6	63
54	Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 10-20.	2.0	63

#	ARTICLE	IF	CITATIONS
55	Numbers of -expressing CD4CD25 T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2005, 33, 894-900.	0.2	61
56	T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis. <i>Journal of Clinical Oncology</i> , 2003, 21, 1271-1277.	0.8	60
57	Mobile applications in oncology: is it possible for patients and healthcare professionals to easily identify relevant tools?. <i>Annals of Medicine</i> , 2016, 48, 509-515.	1.5	60
58	Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2004, 22, 2826-2834.	0.8	59
59	Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. <i>Blood</i> , 2004, 103, 695-697.	0.6	59
60	Modern management of non-Hodgkin lymphoma in HIV-infected patients. <i>British Journal of Haematology</i> , 2007, 136, 685-698.	1.2	57
61	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019, 29, 1243-1257.e10.	7.2	56
62	Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1309-1315.	0.8	55
63	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF- $\kappa$ B-dependent induction of HIF-1 $\alpha$ . <i>Leukemia</i> , 2015, 29, 1163-1176.	3.3	55
64	Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 2006, 107, 4636-4642.	0.6	54
65	Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 2739-2741.	0.8	54
66	Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. <i>Bone Marrow Transplantation</i> , 2007, 40, 831-835.	1.3	53
67	All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , 2004, 15, 1790-1797.	0.6	52
68	Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 262-269.	0.2	52
69	90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 212-218.	0.2	52
70	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4540-4546.	2.0	51
71	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017, 31, 2493-2501.	1.0	51
72	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. <i>Clinical Infectious Diseases</i> , 2015, 61, 1469-1475.	2.9	47

#	ARTICLE	IF	CITATIONS
73	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008, 19, 1875-1881.	0.6	45
74	Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. <i>Blood</i> , 2013, 122, 2402-2411.	0.6	45
75	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013, 14, 931-939.	0.6	43
76	Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study. <i>Blood</i> , 2015, 126, 577-577.	0.6	43
77	Non-Hodgkin's Lymphoma of the Breast: A Report of 19 Cases and a Review of the Literature. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 37-42.	2.1	42
78	A multicentre, phase III trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 334-342.	1.2	40
79	ABVD (8 cycles) versus BEACOPP (4 escalated cycles + 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 8002-8002.	0.8	38
80	Pathologic and Clinical Features of 77 Hodgkin's Lymphoma Patients Treated in a Lymphoma Protocol (LNH87). <i>American Journal of Surgical Pathology</i> , 2001, 25, 297-306.	2.1	37
81	Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. <i>Leukemia</i> , 1998, 12, 213-219.	3.3	33
82	Hodgkin Lymphoma in Patients with HIV Infection: A Review. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 228-234.	1.2	30
83	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	1.3	29
84	Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. <i>Haematologica</i> , 2015, 100, 1579-1586.	1.7	28
85	Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. <i>British Journal of Haematology</i> , 2002, 118, 210-217.	1.2	25
86	Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 1426-1427.	0.8	24
87	A multivariate analysis of the survival of patients with aggressive lymphoma. <i>Cancer</i> , 1998, 82, 1952-1962.	2.0	23
88	Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. <i>Cancer</i> , 2005, 104, 2735-2742.	2.0	23
89	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: Therapeutic implications. <i>European Journal of Cancer</i> , 2012, 48, 3335-3341.	1.3	22
90	Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2006, 91, 715-6.	1.7	22



#	ARTICLE	IF	CITATIONS
91	VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. <i>Cancer</i> , 2008, 112, 433-442.	2.0	21
92	Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. <i>Blood Cancer Journal</i> , 2013, 3, e155-e155.	2.8	21
93	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	2.2	21
94	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. <i>Oncotarget</i> , 2016, 7, 83987-84002.	0.8	20
95	Central nervous system involvement in AIDS-related lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 857-866.	1.2	19
96	Blastic plasmacytoid dendritic cell neoplasm: a report of four cases and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1176-1181.	1.3	18
97	Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2161-2168.	0.6	17
98	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. <i>Oncotarget</i> , 2014, 5, 4384-4391.	0.8	17
99	Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma. <i>Seminars in Oncology</i> , 2004, 31, 12-16.	0.8	16
100	Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 549-555.	1.1	16
101	Hodgkin Lymphoma in HIV Positive Patients. <i>Current HIV Research</i> , 2010, 8, 141-146.	0.2	16
102	Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 151-154.	0.2	16
103	R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study. <i>Blood</i> , 2007, 110, 517-517.	0.6	16
104	Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 28-33.	0.8	15
105	Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden. <i>Cancer</i> , 2010, 116, 4299-4308.	2.0	15
106	Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1239-1248.	0.6	15
107	Monosomal karyotype improves IPSS stratification in MDS and AML patients treated with Azacitidine. <i>American Journal of Hematology</i> , 2013, 88, 780-783.	2.0	15
108	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	1.2	15

#	ARTICLE	IF	CITATIONS
109	Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients. <i>Annals of Oncology</i> , 2001, 12, 1749-1755.	0.6	14
110	High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma. <i>Cancer</i> , 2007, 109, 60-67.	2.0	14
111	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019, 125, 2291-2299.	2.0	14
112	Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. <i>Lymphoma</i> , 2014, 2014, 1-12.	0.2	13
113	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 115.	1.0	13
114	Model-Based Methodology for Analyzing Incomplete Quality-of-Life Data and Integrating Them into the Q-Twist Framework. <i>Medical Decision Making</i> , 2003, 23, 54-66.	1.2	12
115	High-dose therapy for indolent lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 225-239.	2.0	11
116	Fc $\gamma$ RIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , 2004, 18, 2038-2040.	3.3	11
117	Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. <i>Clinical Biochemistry</i> , 2006, 39, 86-90.	0.8	10
118	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. <i>Cancer Medicine</i> , 2018, 7, 539-548.	1.3	10
119	Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. <i>Oncology Reports</i> , 2005, 14, 513.	1.2	9
120	Relapses, treatments and new drugs. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 49-60.	0.7	9
121	Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2019, 33, 993-1000.	1.0	9
122	Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. <i>Current Opinion in Oncology</i> , 2011, 23, 209-213.	1.1	8
123	Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 164.	1.8	8
124	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013, 122, 764-764.	0.6	8
125	Myelodysplasia After Autotransplantation. <i>Journal of Clinical Oncology</i> , 2000, 18, 3446-3447.	0.8	7
126	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. <i>Annals of Oncology</i> , 2008, 19, 560-565.	0.6	7



#	ARTICLE	IF	CITATIONS
127	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020, 34, 599-608.	1.0	7
128	A multivariate analysis of the survival of patients with aggressive lymphoma. <i>Cancer</i> , 1998, 82, 1952-1962.	2.0	7
129	Managing large cell lymphoma. <i>Annals of Oncology</i> , 2006, 17, iv8-iv11.	0.6	6
130	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2025-2031.	0.6	6
131	Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. <i>Blood</i> , 2013, 122, 248-248.	0.6	6
132	Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients. <i>AIDS Research and Therapy</i> , 2014, 11, 38.	0.7	5
133	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020, 188, 413-423.	1.2	5
134	Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. <i>European Journal of Cancer</i> , 2020, 138, 189-192.	1.3	5
135	Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. <i>Aids</i> , 2021, 35, 861-868.	1.0	5
136	Lymphoplasmocytic malignant lymphoma presenting with spinal epidural involvement: Four reports of this uncommon lesion. <i>American Journal of Hematology</i> , 1995, 50, 316-317.	2.0	4
137	New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2011, 86, 619-621.	2.0	4
138	Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients. <i>Transfusion</i> , 2013, 53, 115-122.	0.8	4
139	A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: Results of a phase II study of the Groupe d'Études des Lymphomes de l'Adulte (GELA). <i>Leukemia and Lymphoma</i> , 2007, 48, 691-698.	0.6	3
140	Cancer incidence in the vicinity of a waste incineration plant in the Nice area between 2005 and 2014. <i>Environmental Research</i> , 2020, 188, 109681.	3.7	3
141	Prognostic Impact Of Somatic NOTCH2 Mutation In Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2013, 122, 4247-4247.	0.6	3
142	VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. <i>Oncotarget</i> , 2017, 8, 90808-90824.	0.8	3
143	Pneumoblastoma: a rare lung tumour occurring as a long-term complication after allogeneic haematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 197-198.	1.3	2
144	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. <i>Leukemia and Lymphoma</i> , 2010, 51, 1668-1677.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Quality of life following treatment for B-cell lymphoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 523-532.	0.7	2
146	Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. Expert Review of Hematology, 2015, 8, 205-216.	1.0	2
147	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. Blood, 2015, 126, 517-517.	0.6	2
148	Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. Annals of Hematology, 2022, 101, 317-332.	0.8	2
149	Chemotherapy and Interactions with Combination Antiretroviral Therapy. , 2016, , 207-214.		2
150	First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma. Bone Marrow Transplantation, 2017, 52, 310-312.	1.3	1
151	Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Trials.. Blood, 2006, 108, 397-397.	0.6	1
152	High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls.. Blood, 2008, 112, 2191-2191.	0.6	1
153	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. Journal of Clinical Oncology, 2016, 34, 7518-7518.	0.8	1
154	Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer, 2021, , .	2.0	1
155	Diffuse Large B-Cell Lymphoma. , 2016, , 39-65.		1
156	AIDS-Related Lymphoma. , 2013, , 257-266.		0
157	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. Leukemia and Lymphoma, 2016, 57, 2425-2428.	0.6	0
158	Reply to C.F. Hess et al. Journal of Clinical Oncology, 2017, 35, 374-374.	0.8	0
159	Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 1568-1568.	0.6	0
160	Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol. Blood, 2018, 132, 4132-4132.	0.6	0